Fusion Antibodies (LON:FAB) Reaches New 52-Week High – Time to Buy?

Fusion Antibodies plc (LON:FAB)’s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 10.25 ($0.13) and last traded at GBX 10.23 ($0.13), with a volume of 3693715 shares trading hands. The stock had previously closed at GBX 8.15 ($0.10).

Fusion Antibodies Stock Performance

The firm has a market cap of £9.76 million, a price-to-earnings ratio of -255.85 and a beta of 0.49. The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40. The stock has a fifty day moving average price of GBX 5.36 and a 200-day moving average price of GBX 4.14.

Insider Activity at Fusion Antibodies

In other Fusion Antibodies news, insider Adrian Kinkaid purchased 83,728 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were purchased at an average cost of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,145.46). Company insiders own 11.39% of the company’s stock.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.